Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. / Holst, Jens Juul.
In: Current Opinion in Pharmacology, Vol. 13, No. 6, 12.2013, p. 983-8.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery
AU - Holst, Jens Juul
N1 - Copyright © 2013 Elsevier Ltd. All rights reserved.
PY - 2013/12
Y1 - 2013/12
N2 - Gastric bypass surgery is associated with a major weight loss and often causes remission in patients with type 2 diabetes. Surgery is also associated with dramatic increases in the secretion of the gut hormones, glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), both of which regulate appetite and food intake, while GLP-1 in addition functions as an incretin hormone, stimulating insulin secretion. It has been possible to probe the role of GLP-1 for the diabetes resolution after gastric bypass using a GLP-1 receptor antagonist, and it is clear that the enhanced beta cell sensitivity to glucose which underlies the enhanced insulin secretion in the patients after the operation depends critically on the increased GLP-1 secretion. Both hormones seem to contribute importantly to the reduction in food intake after bypass and, therefore, to the weight loss. Currently, there are no data to indicate that decreased secretion of the hormones is involved in the pathogenesis of obesity and/or diabetes, but impaired secretion generally observed in obesity (and hence also in diabetes) may contribute to the development. Because of these effects receptor agonists for both hormones are currently being developed for the treatment of obesity and diabetes.
AB - Gastric bypass surgery is associated with a major weight loss and often causes remission in patients with type 2 diabetes. Surgery is also associated with dramatic increases in the secretion of the gut hormones, glucagon-like peptide-1 (GLP-1) and peptide YY (PYY), both of which regulate appetite and food intake, while GLP-1 in addition functions as an incretin hormone, stimulating insulin secretion. It has been possible to probe the role of GLP-1 for the diabetes resolution after gastric bypass using a GLP-1 receptor antagonist, and it is clear that the enhanced beta cell sensitivity to glucose which underlies the enhanced insulin secretion in the patients after the operation depends critically on the increased GLP-1 secretion. Both hormones seem to contribute importantly to the reduction in food intake after bypass and, therefore, to the weight loss. Currently, there are no data to indicate that decreased secretion of the hormones is involved in the pathogenesis of obesity and/or diabetes, but impaired secretion generally observed in obesity (and hence also in diabetes) may contribute to the development. Because of these effects receptor agonists for both hormones are currently being developed for the treatment of obesity and diabetes.
KW - Bariatric Surgery
KW - Diabetes Mellitus, Type 2
KW - Eating
KW - Enteroendocrine Cells
KW - Gastrointestinal Hormones
KW - Gastrointestinal Tract
KW - Humans
KW - Obesity
U2 - 10.1016/j.coph.2013.09.014
DO - 10.1016/j.coph.2013.09.014
M3 - Journal article
C2 - 24161809
VL - 13
SP - 983
EP - 988
JO - Current Opinion in Pharmacology
JF - Current Opinion in Pharmacology
SN - 1471-4892
IS - 6
ER -
ID: 117853223